Non-Alcoholic Fatty Liver Disease – Epidemiology – Europe
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of NAFLD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology's NAFLD forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with NAFLD?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NAFLD over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following NAFLD subpopulations:
Non-Alcoholic Fatty Liver Disease - Epidemiology - Europe
Total Prevalence of NAFLD per 1,000 People of All Ages in 2021 and 2031
Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of NAFLD over the Next Ten Years
Total Prevalent Cases
Prevalent Cases with Obesity
Studies Included in the Analysis of NAFLD
Studies Excluded from the Analysis of NAFLD
Risk/Protective Factors for NAFLD
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.